Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JT Licenses Hyperlipidemia Drug to Roche
November 1, 2004
- PRESS SEMINAR
November 1, 2004
- Eisai Machinery Starts Operations on Oct. 1
November 1, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
November 1, 2004
- JPMA Conducts Survey on Compliance with Promotion Code
November 1, 2004
- Fuji Chemical Industry Develops New Filler for Orally Disintegrating Tablets
November 1, 2004
- Novartis' Zometa Approved for Hypercalcemia due to Malignant Tumors
November 1, 2004
- Standard Chemotherapy for NSCLC to Be Specified in GLs
November 1, 2004
- Tsumura Sets Standards for Pesticide Residues in Crude Drugs
November 1, 2004
- REGULATORY NEWS IN BRIEF
November 1, 2004
- JPMA, FPMAJ Call For Preferential Tax System for Orphan Drugs
November 1, 2004
- 35 Healthcare-related Bodies Rally against "Mixed Medical Care"
November 1, 2004
- Wishing to Clarify Real Role of FPMAJ: Chairman Takeda
November 1, 2004
- Korosho Study Group Prepares Package Inserts for Patients
November 1, 2004
- DIAGNOSTIC NEWS IN BRIEF
November 1, 2004
- Korosho Study Group on Vaccination Holds 1st Meeting
November 1, 2004
- BULLETIN
November 1, 2004
- No Consensus on "Method Patents" in Medical Field
November 1, 2004
- Alesion Dry Syrup to Be Approved
November 1, 2004
- MEDICAL DEVICE NEWS IN BRIEF
November 1, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…